A5012745608- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Erythropoietin and Anemia Treatment
- Renal Diseases and Glomerulopathies
- Hemoglobinopathies and Related Disorders
Bayer (Japan)
2024
Bayer (France)
2022
Jikei University School of Medicine
2022
Showa University
2022
ABSTRACT Aims/Introduction This analysis seeks to evaluate the cost‐effectiveness of urine albumin‐to‐creatinine ratio testing compared with protein‐creatinine and no for identification kidney damage in individuals type 2 diabetes who have, or are at risk of, chronic disease Japan. Materials Methods A health‐economic model estimated clinical economic consequences different tests line Japanese guidelines, taking a healthcare perspective. Differences diagnostic performance were considered by...
Abstract Background The objective of this analysis was to estimate the clinical and economic impact undertaking urine albumin-to-creatinine ratio (UACR) testing alongside regular estimated glomerular filtration rate for chronic kidney disease in non-diabetic Japanese patients versus no protein-creatinine (UPCR) testing. Methods An model, taking a healthcare perspective, health-economic UACR over lifetime time horizon. Outcomes reported were additional costs, benefits measured, such as...
Type 2 diabetes (T2D) is a major cause of chronic kidney disease (CKD) in Japan, and there an increasing treatment need for first- second-line care these patients. The addition finerenone to current modalities lowers the risk CKD progression cardiovascular events patients with T2D from Japanese payer perspective. This study investigated cost-effectiveness analysis adding standard (SoC) versus SoC alone T2D. FINE-CKD model validated estimate uses Markov simulate pathway over lifetime horizon....
Erythropoiesis-stimulating agents (ESAs) are the standard treatment for patients with renal anemia to increase hemoglobin (Hb) levels and reduce need blood transfusions. However, treatments targeting high Hb require doses of ESAs administered intravenously, which is associated an elevated risk adverse cardiovascular events. Furthermore, there have been some problems such as variability low achievement target due shorter half-lives ESAs. Consequently, erythropoietin-promoting medications,...
Abstract Erythropoiesis-stimulating agents (ESAs) are a standard treatment for patients with renal anemia to increase hemoglobin (Hb) levels and reduce their need blood transfusions. However, treatments targeting high Hb require doses of ESAs by the intravenous injection which associated an elevated risk adverse cardiovascular events. In response this key limitation other erythropoietin-promoting medications have been developed such as hypoxia-inducible factor-prolyl hydroxylase inhibitors...